

Global, randomized, phase 3 study of tislelizumab + chemotherapy versus placebo + chemotherapy as first-line treatment for advanced/metastatic esophageal squamous cell carcinoma (RATIONALE-306 update): minimum 3-year survival follow-up

Authors: Aziz Zaanan,^{1*} Harry H. Yoon,² Ken Kato,³ Eric Raymond,⁴ Richard Hubner,⁵ Yongqian Shu,⁶ Yueyin Pan,⁷ Yi Jiang,⁸ Jingdong Zhang,⁹ Sook Ryun Park,¹⁰ Takashi Kojima,¹¹ Chen-Yuan Lin,¹² Lucjan Wyrwicz,¹³ David Tougeron,¹⁴ Ryu Ishihara,¹⁵ Liyun Li,¹⁶ Hongqian Wu,¹⁷ Yanyan Peng,¹⁸ Shican Yan,¹⁶ Jianming Xu¹⁹

Affiliations: ¹Hôpital Européen Georges-Pompidou, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France; ²Mayo Clinic, Rochester, MN, USA; ³National Cancer Center Hospital, Tokyo, Japan; ⁴Centre Hospitalier Paris Saint-Joseph, Paris, France; ⁵The Christie NHS Foundation Trust and Division of Cancer Sciences, University of Manchester, Manchester, UK; ⁶The First Affiliated Hospital of Nanjing Medical University, Nanjing, China; ⁷Anhui Provincial Hospital, Hefei, China; ⁸Cancer Hospital of Shantou University Medical College, Shantou, China; ⁹Liaoning Cancer Hospital, Shenyang, China; ¹⁰Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea; ¹¹National Cancer Center Hospital East, Chiba, Japan; ¹²China Medical University Hospital, and China Medical University, Taichung, Taiwan; ¹³Maria Skłodowska-Curie National Cancer Research Institute, Warsaw, Poland; ¹⁴CHU de Poitiers, Poitiers, France; ¹⁵Osaka International Cancer Institute, Osaka, Japan; ¹⁶Clinical Development, BeiGene (Beijing) Co., Ltd., Beijing, China; ¹⁷Global Statistics and Data Science, BeiGene USA, Inc., Ridgefield Park, NJ, USA; ¹⁸Clinical Biomarker, BeiGene (Shanghai) Co., Ltd., Shanghai, China; ¹⁹Fifth Medical Center, Chinese PLA General Hospital, Beijing, China.

ABSTRACT

Introduction: RATIONALE-306 (NCT03783442) is the first global study to investigate anti-programmed cell death protein-1 (PD-1) therapy in combination with different chemotherapy (CT) options in the first-line (1L) treatment of advanced/metastatic esophageal squamous cell carcinoma (ESCC). At interim analysis (IA), tislelizumab (TIS; anti-PD-1 mAb) + CT demonstrated a statistically significant, clinically meaningful improvement in overall survival (OS) versus placebo (PBO) + CT, with a manageable safety profile. Here, we report updated efficacy and safety data with minimum 3 years' follow-up after study unblinding at IA.

Patients and Methods: Eligible adults with previously untreated unresectable locally advanced recurrent/metastatic ESCC and no prior systemic treatment for advanced disease were enrolled and randomized (1:1; stratified by region, prior definitive therapy, and investigator [INV]-chosen CT) to receive TIS 200 mg (Arm A) or PBO (Arm B) intravenously every 3 weeks + CT (platinum + fluoropyrimidine or platinum + paclitaxel), until disease progression or intolerable toxicity. The primary endpoint was OS in the intent-to-treat population. Secondary endpoints included progression-free survival (PFS), objective response rate (ORR), and duration of response (DoR), all per INV, and safety.

Results: In total, 649 patients were randomized (Arm A, n=326; Arm B, n=323). At a minimum study follow-up of 36.0 months, improvements in OS, PFS, and DoR in Arm A versus B (**Table**) were maintained, similar to the IA. The hazard ratio (HR) for OS with TIS + CT versus PBO + CT was 0.70 (95% confidence interval: 0.59-0.83). Similar to the IA, incidences of any-grade (96.6% vs 96.3%) or grade ≥ 3 (67.0% vs 64.5%) treatment-related adverse events (TRAEs) were comparable between Arms A and B, respectively; treatment-emergent adverse events leading to treatment discontinuation were higher in Arm A (32.1%) versus Arm B (22.1%). In Arm A versus Arm B, respectively, serious TRAEs occurred in 29.9% vs 19.6% of patients; TRAEs leading to death occurred in 1.9% and 1.2%, respectively.

Conclusion: After minimum 3 years' follow-up, 1L TIS + CT continued to demonstrate clinically meaningful improvements in OS and PFS and durable antitumor response benefit versus PBO + CT in patients with advanced/metastatic ESCC, with no new safety signals.

Table

	Arm A: TIS + CT (n=326)	Arm B: PBO + CT (n=323)
Median OS, mo (95% CI)	17.2 (15.8, 20.1)	10.6 (9.3, 12.0)
24-mo OS, % (95% CI)	37.9 (32.5, 43.2)	24.8 (20.1, 29.8)
36-mo OS, % (95% CI)	22.1 (17.6, 27.0)	14.1 (10.4, 18.4)
24-mo PFS, % (95% CI)	18.1 (13.6, 23.1)	7.2 (4.4, 11.0)
36-mo PFS, % (95% CI)	15.0 (10.8, 19.9)	2.9 (1.1, 6.2)
24-mo DoR, % (95% CI) ^a	19.9 (14.3, 26.3)	10.1 (5.0, 17.1)
36-mo DoR, % (95% CI) ^a	17.7 (12.3, 24.0)	5.0 (1.5, 11.8)

^aAmong responders (Arm A, n=207; Arm B, n=137)
mo, month(s)